Key facts
- · Type: New offering first sale 2026-02-17 · Amount sold: $200M · Total offering: $200M · SEC filing
- · Type: New offering first sale 2024-01-04 · Amount sold: $80M · Total offering: $240M · SEC filing
- · Type: New offering first sale 2022-10-10 · Amount sold: $60M · Total offering: $60M · SEC filing
Is IMMUNIC, INC. a real, registered company?
IMMUNIC, INC. is a registered filer with the SEC (CIK 1280776) and has filed since 2022-10-18. 3 filings are on record, the latest on 2026-03-04.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
How much has IMMUNIC, INC. raised?
Its new offerings report $340M sold across 3 offerings, as its own filings state.
Run the free check on IMMUNIC, INC. →
NEW YORK, UNITED STATES
Biotechnology
3
$340M
Every filing
| Filed | Type | Amount sold | Total offering | Records |
|---|---|---|---|---|
| 2026-03-04 | New offering first sale 2026-02-17 | $200M | $200M | SEC filing |
| 2024-01-19 | New offering first sale 2024-01-04 | $80M | $240M | SEC filing |
| 2022-10-18 | New offering first sale 2022-10-10 | $60M | $60M | SEC filing |
Keep reading
More on IMMUNIC, INC. and the records around it.
IMMUNIC, INC. elsewhere on the record
- 5%+ stake filings Nov 2026
- Leadership changes Sep 2026
- Form D filing Mar 2026
- Who owns it
Companies that share a holder
- Laurion Capital Management LP also filed stake reports on 2 other companies: Pyxis Oncology, Inc. (Nov 2026), Rallybio Corp (Aug 2026)
- Avidity Partners Management LP also filed stake reports on 5 other companies: Context Therapeutics Inc. (May 2026), Perspective Therapeutics, Inc. (Mar 2026), Scynexis, Inc. (Feb 2026)
- Soleus Private Equity Fund III, L.P. also filed stake reports on 5 other companies: Prelude Therapeutics Inc (Jul 2026), CALCIMEDICA, INC. (May 2026), Aprea Therapeutics, Inc. (Apr 2026)
Watch IMMUNIC, INC.
Get an email when IMMUNIC, INC. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
What do you want to do with IMMUNIC, INC.?
Who to contact
- Daniel Vitt — Executive Officer, Director
- Simona Skerjanec — Director
- Duane Nash — Director
- Tamar Howson — Director
- Joerg Neerman — Director
- Richard Rudick — Director
- Andreas Muehler — Executive Officer
- Patrick Walsh — Executive Officer
- Thorvald Nagel — Director
- Hella Kohlhof — Executive Officer
- Glenn Whaley — Executive Officer
- Inderpal Singh — Executive Officer
- Barclay Phillips — Director
- Jason Tardio — Executive Officer
- Round: Form D filed 2026-03-04
- Amount sold: $200M
- Industry: Biotechnology
- Based: NEW YORK, UNITED STATES
People listed
- Daniel Vitt — Executive Officer, Director
- Simona Skerjanec — Director
- Duane Nash — Director
- Tamar Howson — Director
- Joerg Neerman — Director
- Richard Rudick — Director
- Andreas Muehler — Executive Officer
- Patrick Walsh — Executive Officer
- Thorvald Nagel — Director
- Hella Kohlhof — Executive Officer
- Glenn Whaley — Executive Officer
- Inderpal Singh — Executive Officer
- Barclay Phillips — Director
- Jason Tardio — Executive Officer
- Filing: Form D filed 2026-03-04
- Amount sold: $200M
- Industry group: Biotechnology
- Based: NEW YORK, UNITED STATES
- Entity type: Corporation
We'll show it in your MentionFox inbox when IMMUNIC, INC. raises, hires or launches. No email unless you switch it on.
Watch IMMUNIC, INC. →Want the whole picture on IMMUNIC, INC.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on IMMUNIC, INC.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on IMMUNIC, INC. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
4 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
How the total is counted: the amount sold on each new offering, added together. Amendments are left out, because an amendment restates an offering already counted. A filing whose figures have not been read yet shows a dash and adds nothing.
Every figure here is read from IMMUNIC, INC.'s own filings with the SEC. The people those filings name are on the team page.